Compare MOB & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOB | CING |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | Israel | United States |
| Employees | N/A | 13 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.0M | 93.1M |
| IPO Year | N/A | N/A |
| Metric | MOB | CING |
|---|---|---|
| Price | $4.94 | $5.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $34.50 |
| AVG Volume (30 Days) | 254.1K | ★ 542.3K |
| Earning Date | 03-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $150.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.45 | $3.20 |
| 52 Week High | $11.01 | $11.89 |
| Indicator | MOB | CING |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 37.27 |
| Support Level | $3.62 | $3.58 |
| Resistance Level | $6.64 | $6.85 |
| Average True Range (ATR) | 0.49 | 0.51 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 31.43 | 8.04 |
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.